Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, November 09, 2021
Biosynth Carbosynth and Shengquan announced their acquisition of Kexing Biopharmaceutical's raw material factory in Jinan, China.
read more
Biosynth announced the opening of its expanded GMP bioconjugation facility at its existing Berlin site. This strategic expansion significantly enhances Biosynth's specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, ...
read more
Monday, September 25, 2023
Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support ...
read more
Tuesday, October 03, 2023
Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support ...
read more
Biosynth has acquired Cambridge Research Biochemicals (“CRB”), a producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.
read more
BIOTEM announced the implementation of a new industrial site in Colombe, Isère, located just over a mile (2km) from its current site.
read more
Tuesday, January 15, 2013
Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG (Dreieich, Germany), today announced it has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics,Inc.(ADMA).
read more
Saturday, January 28, 2017
Biotest Pharmaceuticals Corporation has announced the relocation of its Gainesville plasma collection center to 2315 NW 13th Street, Gainesville, Florida. The 15,000 square foot state-of-the-art facility officially opened its doors for business on ...
read more
Wednesday, December 07, 2016
Biothera Pharmaceuticals has announced an expansion of its research collaboration with Merck (known as MSD outside the United States and Canada) to include a Phase 2 clinical study investigating Biothera’s Imprime PGG in combination with KEYTRUDA® (...
read more
BioVaxys announced that its bioproduction partner Bio Elpida of Lyon, France, has initiated the construction of a new Good Manufacturing Practice ("GMP") cleanroom facility needed for producing the clinical supply of BVX-0918A, BioVaxys' ovarian ...
read more
Tuesday, December 17, 2024
BioVaxys Technology Corp. announced that in anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, it has acquired a 48-kilogram ("kg") supply of GMP-grade lipid to enable production of the ...
read more
BioVaxys has entered into an agreement with Bioanalytical Systems to conduct preclinical toxicology studies for its Covid-T immunodiagnostic.
read more
Saturday, September 25, 2021
ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing and BIOVECTRA, a CDMO specializing in clinical-to-commercial scale production of high-quality regulated Biologics, Active Pharmaceutical Ingredients, and...
read more
BioVectra announced a five-year, $144.6 million (CAD) expansion project to enhance its Biopharmaceutical capabilities in both Charlottetown, Prince Edward Island and Windsor, Nova Scotia.
read more
Thursday, November 18, 2021
BIOVECTRA has announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada.
read more